Avalo Therapeutics (AVTX) to Release Earnings on Monday

Avalo Therapeutics (NASDAQ:AVTX) is anticipated to issue its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($1.1776) per share and revenue of $0.0520 million for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

Avalo Therapeutics (NASDAQ:AVTX) last announced its earnings results on Monday, March 23rd. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.54) by $1.17. The business had revenue of $0.06 million for the quarter, compared to the consensus estimate of ($0.21) million. On average, analysts expect Avalo Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Avalo Therapeutics Stock Up 0.5%

Shares of NASDAQ AVTX traded up $0.07 on Monday, reaching $13.78. 52,775 shares of the company’s stock traded hands, compared to its average volume of 606,242. Avalo Therapeutics has a 12 month low of $3.39 and a 12 month high of $20.72. The business’s 50 day simple moving average is $15.29 and its two-hundred day simple moving average is $16.22. The company has a market cap of $367.99 million, a price-to-earnings ratio of -2.39 and a beta of 0.78.

Insider Activity at Avalo Therapeutics

In related news, CFO Christopher Ryan Sullivan sold 8,457 shares of the firm’s stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $13.23, for a total transaction of $111,886.11. Following the completion of the sale, the chief financial officer owned 423 shares of the company’s stock, valued at $5,596.29. This trade represents a 95.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 3,970 shares of the firm’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $18.01, for a total transaction of $71,499.70. Following the sale, the insider directly owned 3,622 shares of the company’s stock, valued at $65,232.22. This trade represents a 52.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 63,015 shares of company stock valued at $987,326 in the last three months. 4.46% of the stock is owned by insiders.

Institutional Investors Weigh In On Avalo Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Orbimed Advisors LLC increased its position in shares of Avalo Therapeutics by 39.5% during the third quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company’s stock valued at $17,150,000 after acquiring an additional 382,300 shares in the last quarter. Nantahala Capital Management LLC increased its position in shares of Avalo Therapeutics by 24.1% during the third quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company’s stock valued at $15,697,000 after acquiring an additional 240,000 shares in the last quarter. Affinity Asset Advisors LLC increased its position in shares of Avalo Therapeutics by 4.5% during the fourth quarter. Affinity Asset Advisors LLC now owns 1,051,054 shares of the company’s stock valued at $19,087,000 after acquiring an additional 44,837 shares in the last quarter. Caligan Partners LP increased its position in shares of Avalo Therapeutics by 5.8% during the fourth quarter. Caligan Partners LP now owns 881,533 shares of the company’s stock valued at $16,009,000 after acquiring an additional 48,200 shares in the last quarter. Finally, Balyasny Asset Management L.P. bought a new stake in shares of Avalo Therapeutics during the third quarter valued at approximately $10,390,000. Institutional investors own 87.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on AVTX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avalo Therapeutics in a research note on Wednesday, April 8th. BTIG Research reaffirmed a “buy” rating and set a $40.00 target price on shares of Avalo Therapeutics in a research note on Monday, April 13th. Citizens Jmp began coverage on shares of Avalo Therapeutics in a research note on Monday, April 6th. They set an “outperform” rating and a $52.00 target price for the company. Wall Street Zen raised shares of Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, March 29th. Finally, HC Wainwright raised their target price on shares of Avalo Therapeutics from $25.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Avalo Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.83.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.